Pharmaceutical - Johnson & Johnson, Licensing


Popular Filters

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

AstraZeneca to co-promote Janssen prostate cancer drug in Japan


Anglo-Swedish drug major AstraZeneca has entered into an agreement with US health care giant Johnson…

abirateroneAsia-PacificAstraZenecaJanssenJohnson & JohnsonLicensingMarkets & MarketingOncologyPharmaceuticalZytiga

Janssen gains rights to Ph II hepatitis C candidate from GSK


Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Mitsubishi Tanabe succeeds in arbitration


Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) says it has been awarded $117 million in an…

Anti-Arthritics/RheumaticsAsia-PacificJanssen BiotechJohnson & JohnsonLicensingMitsubishi TanabePharmaceuticalPricingRemicade

Second Genome in deal with Janssen on microbiome drug discovery in ulcerative colitis


Second Genome has entered into an agreement with Janssen Biotech, a subsidiary of US health care giant…

Gastro-intestinalsJanssenJohnson & JohnsonLicensingPharmaceuticalResearchSecond Genome

Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen


Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer…

BiotechnologyDekavilGlycoVaxynInflammatory diseasesJanssenJohnson & JohnsonLicensingPfizerPharmaceuticalPhilogenVaccines

Evotec in up to $175 million NMDA antagonist license deal with Janssen


Germany's Evotec (EVT: TecDAX) has entered into a license agreement with Janssen Pharmaceuticals, a subsidiary…

EvotecJanssenJohnson & JohnsonLicensingNeurologicalPharmaceutical

Merck & Co in Nanobody deal with Ablynx; J&J and Astellas join forces on RA


US pharma giant Merck & Co (NYSE: MRK) has entered into a collaboration with Belgium's Ablynx (Euronext…

AblynxAnti-Arthritics/RheumaticsASPO15KAstellas PharmaBiotechnologyJohnson & JohnsonLicensingMerck & CoPharmaceutical

Johnson & Johnson to set up innovation centers to accelerate partnering


US health care giant Johnson & Johnson (NYSE: JNJ) yesterday said it plans to establish four regional…

Johnson & JohnsonLicensingMergers & AcquisitionsPharmaceuticalResearch

ImmuNext partners with Janssen in up to $150 million cancer discover deal


Closely-held USA-based ImmuNext has entered into an agreement with Janssen Biotech, a unit of US health…

ImmuNextJanssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalResearch

Genmab leaps on $1.1 billion daratumumab deal with Janssen


Denmark's Genmab A/S (OMX: GEN) saw its shares leap 20% to 81 Danish kroner in morning trading yesterday,…

BiotechnologydaratumumabFinancialGenmabHuMax-CD38JanssenJohnson & JohnsonLicensingOncologyPharmaceutical

Genmab in collaboration with Janssen for DuoBody platform


Denmark-based Genmab A/S (OMX: GEN) says it has entered into a collaboration with Janssen Biotech, a…

BiotechnologyDuoBodyGenmabJanssen BiotechJohnson & JohnsonLicensingNovartisPharmaceutical

Furiex Pharma gets rights to Priligy, some of which it sells on to Menarini


In a two part transaction, USA-based Furiex Pharmaceuticals (Nasdaq: FURX) has entered into an agreement…

ALZA CorpFuriex PharmaceuticalsJanssen PharmaceuticaJohnson & JohnsonLicensingMen's HealthMenariniPharmaceuticalPriligy

Bristol-Myers expands hepatitis C accord with Medivir and Janssen


Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

Forest Labs buys Bystolic rights from Janssen for $357 million


Forest Laboratories, (NYSE: FRX) says it has acquired all US patents and other US and Canadian intellectual…

BystolicCardio-vascularForest LaboratoriesJanssen PharmaceuticaJohnson & JohnsonLicensingNorth AmericaPharmaceuticalSavella

Janssen drops deal with Orexo for OX-CLI/OX-ESI


US health care major Johnson & Johnson INYSE: JNJ) subsidiary Janssen has decided to end research collaboration…

FinancialJanssenJohnson & JohnsonLicensingOrexo ABPharmaceuticalRespiratory and Pulmonary

Another mega deal for FORMA Therapeutics


Hot on the heels of its up to $815 million oncology-related deal with Boehringer Ingelheim (The Pharma…

BiotechnologyFORMA TherapeuticsJanssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalResearch

Phylogica signs deal with Johnson & Johnson unit


Australian peptide drug discovery company Phylogica (ASX: PYC) has entered into a collaboration and option…

BiotechnologyFinancialJanssen BiotechJohnson & JohnsonLicensingPharmaceuticalPhylogica

Metamark could earn over $365 million from Janssen deal


Privately-held US firm Metamark Genetics has entered into a research, collaboration and license agreement…

Janssen BiotechJohnson & JohnsonLicensingMetamark GeneticsOncologyPharmaceuticalResearch

J&J to pay nearly $1 billion for cancer drug candidate


US health care giant Johnson & Johnson (NYSE: JNJ), through its subsidiary Janssen Biotech, has executed…

Janssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalPharmacyclics

Gilead in another licensing deal with J&J unit for combo HIV/AIDS treatment


US biotech firm Gilead Sciences (Nasdaq: GILD) has entered into a license agreement with Tibotec Pharmaceuticals,…

Anti-viralsBiotechnologycobicistatEmtrivaGilead SciencesJohnson & JohnsonLicensingPharmaceuticalPrezistaResearchTibotec

Back to top